Chief Medical Officer
Dr. Viktor Boerlin is the Chief Medical Officer at Strekin. Dr. Boerlin worked for over 30 years for Sandoz/Novartis and Hoffmann-La Roche in different positions and therapeutic areas overseeing drug development encompassing Phase 1 to Phase 4 clinical trials. At Sandoz, he led the Department of Neuroendocrinology in clinical R&D where he was responsible for the clinical sections of seven registration filings. Dr. Boerlin served at Sandoz for 3 years as Medical Director in Japan. After his return to Headquarters, he led the phase 4 activities for somatostatin analogs at Novartis and early development for a new molecule of this class. In 2004, Dr. Boerlin took on a new challenge as medical liaison between clinical, preclinical and partnering for projects in type 2 diabetes at Hoffmann-La Roche. Later he became the clinical leader for development of a novel PPAR α/γ agonist and an SGLT2 inhibitor. Dr. Boerlin obtained his M.D. at Basel University Medical School.